{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:47:49Z","timestamp":1793047669846,"version":"4.5.0"},"reference-count":97,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T00:00:00Z","timestamp":1474934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dentistry Journal"],"abstract":"<jats:p>Medication-related osteonecrosis of the jaw is a known side-effect of antiresorptive therapy in patients with malignant diseases. Nevertheless, the exact pathogenesis is still unknown and published prevalences show a significant range. The aim of the presented paper was to assess the prevalence of osteonecrosis (ONJ) in breast cancer, prostate cancer, and multiple myeloma patients receiving parenteral antiresorptive therapy. For this reason a PubMed search was performed and 69 matching articles comprising 29,437 patients were included in the analysis. Nine-hundred fifty-one cases of jaw necrosis were described. The overall ONJ-prevalence was 2.09% in the breast cancer group, 3.8% in the prostate cancer group, and 5.16% for multiple myeloma patients.<\/jats:p>","DOI":"10.3390\/dj4040032","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T05:57:13Z","timestamp":1474955833000},"page":"32","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma"],"prefix":"10.3390","volume":"4","author":[{"given":"Petra","family":"Rugani","sequence":"first","affiliation":[{"name":"Divison of Oral Surgery and Orthodontics, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Walter","sequence":"additional","affiliation":[{"name":"Oral and Maxillofacial Surgery of the Mediplus Clinic, 55128 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kirnbauer","sequence":"additional","affiliation":[{"name":"Divison of Oral Surgery and Orthodontics, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8111-156X","authenticated-orcid":false,"given":"Stephan","family":"Acham","sequence":"additional","affiliation":[{"name":"Divison of Oral Surgery and Orthodontics, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Begus-Nahrman","sequence":"additional","affiliation":[{"name":"Konzept Pharma Service GmbH, 31084 Freden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Jakse","sequence":"additional","affiliation":[{"name":"Divison of Oral Surgery and Orthodontics, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.joms.2003.09.001","article-title":"Avascular necrosis of the jaws: Risk factors in metastatic cancer patients","volume":"61","author":"Tarassoff","year":"2003","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_3","first-page":"S2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00784-009-0365-2","article-title":"Bisphosphonates: Restrictions for vasculogenesis and angiogenesis: Inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro","volume":"15","author":"Ziebart","year":"2011","journal-title":"Clin. Oral Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00784-009-0300-6","article-title":"Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: A possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings","volume":"14","author":"Hoefert","year":"2010","journal-title":"Clin. Oral Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00784-009-0294-0","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: What do we currently know? A survey of knowledge given in the recent literature","volume":"14","author":"Rustemeyer","year":"2010","journal-title":"Clin. Oral Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: So many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, and American Association of Oral and Maxillofacial Surgeons (2007). American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg., 65, 369\u2013376.","DOI":"10.1016\/j.joms.2006.11.003"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.amjmed.2010.04.033","article-title":"Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: A case series","volume":"123","author":"Fedele","year":"2010","journal-title":"Am. J. Med."},{"key":"ref_10","first-page":"1233","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates. Discussion over 52 cases","volume":"52","author":"Rotaru","year":"2011","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/030089161109700411","article-title":"Bisphosphonate-induced osteonecrosis of the jaw in patients with bone metastatic, hormone-sensitive prostate cancer. Risk factors and prevention strategies","volume":"97","author":"Bantis","year":"2011","journal-title":"Tumori"},{"key":"ref_12","first-page":"b147","article-title":"Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: A review of 282 patients","volume":"77","author":"Bonacina","year":"2011","journal-title":"J. Can. Dent. Assoc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.oraloncology.2011.11.004","article-title":"The Saxon Bisphosphonate Register\u2014Therapy and prevention of bisphosphonate-related osteonecrosis of the jaws","volume":"48","author":"Schubert","year":"2011","journal-title":"Oral Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1746-160X-6-11","article-title":"Prevalence of bisphosphonate associate osteonecrosis of the jaws in multiple myeloma patients","volume":"6","author":"Walter","year":"2010","journal-title":"Head Face Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1634\/theoncologist.10-10-842","article-title":"Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years","volume":"10","author":"Guarneri","year":"2005","journal-title":"Oncologist"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_21","first-page":"576","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid","volume":"127","year":"2006","journal-title":"Med. Clin."},{"key":"ref_22","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/annonc\/mdl163","article-title":"Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer","volume":"17","author":"Sanna","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2006-07-033571","article-title":"Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone","volume":"108","author":"Tosi","year":"2006","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in303patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/02841860500341173","article-title":"Jaw complications in breast and prostate cancer patients treated with zoledronic acid","volume":"45","author":"Ortega","year":"2006","journal-title":"Acta Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/annonc\/mdl408","article-title":"Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis","volume":"18","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","article-title":"A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma","volume":"21","author":"Corso","year":"2007","journal-title":"Leukemia"},{"key":"ref_29","first-page":"E351","article-title":"Osteonecrosis of the jaw as an adverse bisphosphonate event: Three cases of bone metastatic prostate cancer patients treated with zoledronic acid","volume":"12","author":"Villalobos","year":"2007","journal-title":"Med. Oral Patol. Oral Cir. Bucal"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/annonc\/mdm370","article-title":"A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients","volume":"18","author":"Jadu","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1080\/02841860601185917","article-title":"Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: A retrospective analysis","volume":"46","author":"Ortega","year":"2007","journal-title":"Acta Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3324\/haematol.11096","article-title":"Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients","volume":"92","author":"Petrucci","year":"2007","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.joms.2007.03.006","article-title":"Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy","volume":"65","author":"Wang","year":"2007","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/10428190600977690","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: A review of 35 cases and an evaluation of its frequency in multiple myeloma patients","volume":"48","author":"Pozzi","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.oraloncology.2007.11.012","article-title":"Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies","volume":"44","author":"Boonyapakorn","year":"2008","journal-title":"Oral Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ygyno.2008.11.029","article-title":"Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies","volume":"112","author":"Fehm","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1634\/theoncologist.2007-0159","article-title":"Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: A retrospective study","volume":"13","author":"Ibrahim","year":"2008","journal-title":"Oncologist"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.eururo.2008.06.070","article-title":"Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate","volume":"54","author":"Walter","year":"2008","journal-title":"Eur. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1349-7006.2008.00803.x","article-title":"Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases","volume":"99","author":"Yonemori","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1634\/theoncologist.2008-0091","article-title":"Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy","volume":"13","author":"Estilo","year":"2008","journal-title":"Oncologist"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/10428190802483778","article-title":"Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates","volume":"49","author":"Montefusco","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/cncr.24119","article-title":"Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients","volume":"115","author":"Walter","year":"2009","journal-title":"Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/07357900802208608","article-title":"Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents","volume":"27","author":"Ning","year":"2009","journal-title":"Cancer Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00774-009-0047-9","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid","volume":"27","author":"Cetiner","year":"2009","journal-title":"J. Bone Miner. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3109\/07357900902783203","article-title":"Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer","volume":"27","author":"Crawford","year":"2009","journal-title":"Cancer Investig."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3109\/00365590903295193","article-title":"Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw","volume":"43","author":"Haidar","year":"2009","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12032-009-9195-y","article-title":"Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: A long-term retrospective analysis","volume":"27","author":"Bonomi","year":"2009","journal-title":"Med. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/hed.20941","article-title":"Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws","volume":"31","author":"Stumpe","year":"2009","journal-title":"Head Neck"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","article-title":"Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): A double-blind, randomised controlled trial","volume":"11","author":"Gimsing","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_58","first-page":"39","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates","volume":"31","author":"Pavkovic","year":"2010","journal-title":"Prilozi"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1524-4741.2011.01119.x","article-title":"Osteonecrosis of the jaw in patients with metastatic breast cancer: Ethnic and socio-economic aspects","volume":"17","author":"Quispe","year":"2011","journal-title":"Breast J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.breast.2012.04.008","article-title":"Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis","volume":"21","author":"Ding","year":"2012","journal-title":"Breast"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"E520","DOI":"10.1111\/j.1464-410X.2012.11205.x","article-title":"Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel","volume":"110","author":"Miyazaki","year":"2012","journal-title":"BJU Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COC.0b013e3182155fcb","article-title":"A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates","volume":"35","author":"Tu","year":"2012","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00784-013-1012-5","article-title":"Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer","volume":"18","author":"Rugani","year":"2014","journal-title":"Clin. Oral Investig."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1159\/000343950","article-title":"Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation","volume":"35","author":"Then","year":"2012","journal-title":"Onkologie"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1158\/1078-0432.CCR-11-3310","article-title":"Bone-related complications and quality of life in advanced breast cancer: Results from a randomized phase III trial of denosumab versus zoledronic acid","volume":"18","author":"Martin","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_71","first-page":"3917","article-title":"Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies","volume":"33","author":"Assaf","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_73","first-page":"504","article-title":"Long-term Treatment with Intravenous Bisphosphonates in Metastatic Breast Cancer: A Retrospective Study","volume":"19","author":"Brufsky","year":"2013","journal-title":"Breast J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1200\/JCO.2012.46.4792","article-title":"Osteonecrosis of the jaw and oral health\u2013related quality of life after adjuvant zoledronic acid: An Adjuvant Zoledronic Acid to Reduce Recurrence Trial subprotocol (BIG01\/04)","volume":"31","author":"Rathbone","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1470-2045(13)70539-4","article-title":"Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metasta-ses from breast cancer: A randomised, open label, non-inferiority phase 3 trial","volume":"15","author":"Casbard","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"Adjuvant zoledronic acid in patients with early breast cancer: Final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/bjh.12861","article-title":"Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results","volume":"166","author":"Jackson","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: Final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_79","first-page":"e267","article-title":"Osteonecrosis of the jaws in 194 patients who have undergone intravenous bisphosphonate therapy in Spain","volume":"20","year":"2015","journal-title":"Med. Oral Patol. Oral Cir. Bucal"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.clgc.2014.10.001","article-title":"Safety of IV Nonnitrogen Bisphosphonates on the Occurrence of Osteonecrosis of the Jaw: Long-Term follow-up on Prostate Cancer Patients","volume":"13","author":"Rodrigues","year":"2015","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","article-title":"Safety of long-term denosumab therapy: Results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/clr.12556","article-title":"Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials","volume":"27","year":"2016","journal-title":"Clin. Oral Implants Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1111\/j.1834-7819.2005.tb00384.x","article-title":"The dental implications of bisphosphonates and bone disease","volume":"50","author":"Cheng","year":"2005","journal-title":"Aust. Dent. J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.joms.2008.11.015","article-title":"Bisphosphonate-related osteonecrosis of the jaws: A single-center study of 101 patients","volume":"67","author":"Lazarovici","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_85","first-page":"52","article-title":"Osteonekrose des Kiefers unter Bisphosphonat-Langzeittherapie","volume":"3","author":"Diel","year":"2005","journal-title":"Im Focus Onkol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jcms.2007.06.008","article-title":"\u201cBis-phossy jaws\u201d\u2014High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw","volume":"36","author":"Warnke","year":"2008","journal-title":"J. Cranio-Maxillo-Fac. Surg."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jcms.2011.05.003","article-title":"Bisphosphonate-related osteonecrosis of the jaws\u2014Characteristics, risk factors, clinical features, localization and impact on oncological treatment","volume":"40","author":"Otto","year":"2012","journal-title":"J. Cranio-Maxillo-Fac. Surg."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s12105-007-0022-5","article-title":"Bisphosphonate-induced osteonecrosis of the jaws: Review, clinical implications and case report","volume":"1","author":"Suleman","year":"2007","journal-title":"Head Neck Pathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1600-051X.2005.00842.x","article-title":"Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment","volume":"32","author":"Ficarra","year":"2005","journal-title":"J. Clin. Periodontol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1038\/sj.bdj.2013.327","article-title":"A study of 225 patients on bisphosphonates presenting to the bisphosphonate clinic at King\u2019s College Hospital","volume":"214","author":"Taylor","year":"2013","journal-title":"Br. Dent. J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.joms.2009.10.026","article-title":"Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction","volume":"68","author":"Saia","year":"2010","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jpor.2014.08.001","article-title":"Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab","volume":"59","author":"Niibe","year":"2015","journal-title":"J. Prosthodont. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/dj4020017","article-title":"Diabetes Mellitus and Its Association to the Occurrence of Medication-Related Osteonecrosis of the Jaw","volume":"4","author":"Sagheb","year":"2016","journal-title":"Dent. J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e752","DOI":"10.4317\/medoral.18076","article-title":"Bisphosphonate-related osteonecrosis of the jaws (Bronj)","volume":"18","author":"Beninati","year":"2013","journal-title":"Med. Oral Patol. Oral Cir. Bucal"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1210\/jc.2015-1794","article-title":"Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer","volume":"100","author":"Sanders","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.oraloncology.2008.01.012","article-title":"Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates","volume":"44","author":"Bagan","year":"2008","journal-title":"Oral Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx","year":"2007","journal-title":"J. Oral Maxillofac. Surg."}],"container-title":["Dentistry Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2304-6767\/4\/4\/32\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:31:51Z","timestamp":1760211111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2304-6767\/4\/4\/32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,27]]},"references-count":97,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,12]]}},"alternative-id":["dj4040032"],"URL":"https:\/\/doi.org\/10.3390\/dj4040032","relation":{},"ISSN":["2304-6767"],"issn-type":[{"value":"2304-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,27]]}}}